Osteocytes, RANKL and bone loss.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Endogenous Osteocyte-Osteoclast Signaling Enables Growth Factor-Free Bone Remodeling, Drug Response, and Cancer Invasion in a Nanoscale Calcified Bone-on-a-Chip Model.bioRxiv : the preprint server for biology · 2025
   Article
2. IL-27 Modulates the Cytokine Secretion in the T Cell-Osteoclast Crosstalk During HIV Infection.Frontiers in immunology · 2022
   Article
3. Mechanisms of acute hypercalcemia in pediatric patients following the interruption of Denosumab.Journal of endocrinological investigation · 2022
   Article
4. Enhanced hematopoietic stem cell function mediates immune regeneration following sex steroid blockade.Stem cell reports · 2015
   Article

Corrections and comments

• Comment on
  Matrix-embedded cells control osteoclast formation.2011
• Comment on
  Evidence for osteocyte regulation of bone homeostasis through RANKL expression.2011

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.